Organization (Hospital)
Western Sydney Local Health District
ClinicalTrials.gov lists Western Sydney Local Health District as lead sponsor of 38 trials, counting the companies grouped under it. Western Sydney Local Health District itself has 30 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers Western Sydney Local Health District and 1 company grouped under it: 38 lead-sponsored trials (36 its own, 2 in the grouped companies) and 2 legal-entity registrations (1 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Westmead Hospital | 2 | 1 |
Disease areas (67)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Colorectal Neoplasms | 7 |
| Polyps | 7 |
| Colonic Polyps | 4 |
| Head and Neck Neoplasms | 4 |
| Kidney Neoplasms | 3 |
Showing 5 of 67 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 5 |
| 2024 | 4 |
| 2023 | 6 |
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 4 |
Showing 10 of 16 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 14 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (30)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Acetylcysteine | Huntington Disease | Phase 2 | 1 |
| Acetylcysteine | Dementia | Phase 2 | 1 |
| Cephalexin | Tuberculosis, Pulmonary | Phase 2 | 1 |
| Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet | Tuberculosis, Pulmonary | Phase 2 | 1 |
| Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet | Tuberculosis | Phase 2 | 1 |
Showing 5 of 30 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Cephalexin | 1 |
| METFORMIN | 1 |
| Acetylcysteine | 1 |
| Tamoxifen | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=9) | 22% on time (n=9) |
Journals published in (22)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Gastrointestinal endoscopy | 7 |
| Endoscopy | 5 |
| The American journal of gastroenterology | 4 |
| Gastroenterology | 3 |
| Gut | 3 |
Showing 5 of 22 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 16 | 5 | 2025-12-23 |
Organization relationships (37)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Peter MacCallum Cancer Centre, Australia | Co sponsors trial with | 4 |
| The University of Sydney | Co sponsors trial with | 3 |
| Melbourne Health | Co sponsors trial with | 2 |
| Monash University | Co sponsors trial with | 2 |
| Western Sydney University | Co sponsors trial with | 2 |
Showing 5 of 37 relationships.
Latest dated events (70)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 70 events.
Biomarker capability evidence (25)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| FAP | Trial sponsor | Named in trial inclusion criteria |
| FAP | Trial sponsor | Named in trial inclusion criteria |
| HTT | Trial sponsor | Named in trial inclusion criteria |
| NADK | Trial sponsor | Named in trial inclusion criteria |
| NADK | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 25 evidence rows.
Biomarkers this organization publishes on (349)
Shown in this order: most publications first.
Showing 5 of 349 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.